Table 1 Demographic and pathological characteristics according to tumor location: overall cohort and matched cohort
Variables | Overall patients | Matched patients | ||||
|---|---|---|---|---|---|---|
LRC (n = 138) | M/HRC (n = 235) | P value | LRC (n = 99) | M/HRC (n = 99) | P value | |
Sex, n (%) | 0.700 | 1.000 | ||||
Male | 78 (56.5) | 128 (54.5) | 52 (52.5) | 52 (52.5) | ||
Female | 60 (43.5) | 107 (45.5) | 47 (47.5) | 47 (47.5) | ||
Age (y), n (%) | 0.027 | 0.802 | ||||
≤ 60 | 81 (58.7) | 110 (46.8) | 54 (54.5) | 58 (58.6) | ||
>60 | 57 (41.3) | 125 (53.2) | 45 (45.5) | 41 (41.4) | ||
ASA, n (%) | 0.873 | 1.000 | ||||
I | 68 (49.3) | 112 (47.7) | 51 (51.5) | 51 (51.5) | ||
II | 57 (41.3) | 97 (41.3) | 39 (39.4) | 39 (39.4) | ||
III | 13 (9.4) | 26 (11.1) | 9 (9.1) | 9 (9.1) | ||
BMI (kg/m2), n (%) | 0.113 | 0.669 | ||||
<25 | 73 (52.9) | 144 (61.3) | 52 (52.5) | 55 (55.6) | ||
≥ 25 | 65 (47.1) | 91 (38.7) | 47 (47.5) | 44 (44.4) | ||
Preoperative CEA (ng/ml), n (%) | 0.374 | 0.644 | ||||
≤ 5 | 100 (72.5) | 160 (68.1) | 67 (67.7) | 70 (70.7) | ||
>5 | 38 (27.5) | 75 (31.9) | 32 (32.3) | 29 (29.3) | ||
Preoperative CA19–9 (U/ml), n (%) | 0.665 | 0.621 | ||||
≤ 37 | 128 (92.8) | 215 (91.5) | 91 (91.9) | 89 (89.9) | ||
>37 | 10 (7.2) | 20 (8.5) | 8 (8.1) | 10 (10.1) | ||
Preoperative CA72.4 (U/ml), n (%) | 0.311 | 0.267 | ||||
≤ 6.7 | 121 (87.7) | 197 (83.8) | 85 (85.9) | 90 (90.9) | ||
>6.7 | 17 (12.3) | 38 (16.2) | 14 (14.1) | 9 (9.1) | ||
Tumor differentiation, n (%) | 0.161 | 0.592 | ||||
Well + moderate | 111 (80.4) | 202 (86.0) | 81 (81.8) | 78 (78.8) | ||
Poor | 27 (19.6) | 33 (14.0) | 18 (18.2) | 21 (21.2) | ||
Pathological T stage, n (%) | <0.001 | 0.461 | ||||
pT0–2 | 64 (46.4) | 66 (28.1) | 39 (39.4) | 34 (34.3) | ||
pT3–4 | 74 (53.6) | 169 (71.9) | 60 (60.6) | 65 (65.7) | ||
Pathological N stage, n (%) | 0.352 | 0.394 | ||||
pN0 | 82 (59.4) | 128 (54.5) | 52 (52.5) | 46 (46.5) | ||
pN1–2 | 56 (40.6) | 107 (45.5) | 47 (47.5) | 53 (53.5) | ||
TNM stage, n (%) | 0.002 | 0.606 | ||||
0-I | 52 (37.7) | 51 (21.7) | 31 (31.3) | 25 (25.3) | ||
II | 30 (21.7) | 77 (32.8) | 21 (21.2) | 21 (21.2) | ||
III | 56 (40.6) | 107 (45.5) | 47 (47.5) | 53 (53.5) | ||
Lymphovascular invasion, n (%) | 13 (9.4) | 37 (15.7) | 0.083 | 11 (11.1) | 13 (13.1) | 0.663 |
Perineural invasion, n (%) | 2 (1.4) | 18 (7.7) | 0.009 | 2 (2.0) | 1 (1.0) | 1.000 |
Neoadjuvant therapy, n (%) | 66 (47.8) | 27 (11.5) | <0.001 | 30 (30.3) | 25 (25.3) | 0.428 |
Adjuvant chemotherapy, n (%) | 80 (58.0) | 117 (49.8) | 0.126 | 59 (59.6) | 64 (64.6) | 0.464 |